<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">anatomy</journal-id><journal-title-group><journal-title xml:lang="ru">Журнал анатомии и гистопатологии</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of Anatomy and Histopathology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2225-7357</issn><publisher><publisher-name>N.N. Burdenko Voronezh State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18499/2225-7357-2025-14-4-21-33</article-id><article-id custom-type="elpub" pub-id-type="custom">anatomy-2176</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>Гистологическая и иммуногистохимическая   оценка тканей иммунодефицитных мышей с   ксенографтами опухоли после введения   NK-клеток человека</article-title><trans-title-group xml:lang="en"><trans-title>Histological and immunohistochemical evaluation of tissues  from immunodeficient mice with of tumor xenografts following administration of human NK cells</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3881-3221</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абакушина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Abakushina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Абакушина Елена Вячеславовна – д-р. мед. наук</p><p>Москва</p></bio><bio xml:lang="en"><p>Elena V. Abakushina – Doct. Sci. (Med.)</p><p>Moscow</p></bio><email xlink:type="simple">abakushina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1316-398X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Степанова</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Stepanova</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Степанова Ирина Анатольевна – канд. биол. наук, старший научный сотрудник</p><p> ул. Дмитрия Ульянова, 11, Москва, 117292</p></bio><bio xml:lang="en"><p>Irina A. Stepanova – Cand. Sci. (Biol.), Senior Researcher</p><p>ul. Dmitriya Ul'yanova, 11, Moscow, 117292</p></bio><email xlink:type="simple">IrinkaStepanova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7418-0222</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Румянцев</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Rumyantsev</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Румянцев Сергей Александрович – д-р. мед. наук, профессор, чл.-корр. РАН</p><p>Москва</p></bio><bio xml:lang="en"><p>Sergei A. Rumyantsev – Doct. Sci. (Med.), Professor, Corresponding Member of RAS</p><p>Moscow</p></bio><email xlink:type="simple">s_roumiantsev@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ООО «Текон МП»; Национальный медицинский исследовательский центр эндокринологии имени академика И.И. Дедова</institution></aff><aff xml:lang="en"><institution>Tekon MP LLC; I.I. Dedov National Medical Research Center of Endocrinology</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр эндокринологии имени академика И.И. Дедова</institution></aff><aff xml:lang="en"><institution>I.I. Dedov National Medical Research Center of Endocrinology</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>28</day><month>01</month><year>2026</year></pub-date><volume>14</volume><issue>4</issue><fpage>21</fpage><lpage>33</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Абакушина Е.В., Степанова И.А., Румянцев С.А., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Абакушина Е.В., Степанова И.А., Румянцев С.А.</copyright-holder><copyright-holder xml:lang="en">Abakushina E.V., Stepanova I.A., Rumyantsev S.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://anatomy.elpub.ru/jour/article/view/2176">https://anatomy.elpub.ru/jour/article/view/2176</self-uri><abstract><p>Иммуноонкология – активно развивающаяся область научно-прикладных исследований, которая произвела революцию в лечении рака. В частности, NK-клетки классифицируются как цитотоксические лимфоциты, которые играют решающую роль в распознавании и устранении злокачественных или инфицированных клеток. Цель исследования – проведение гистологической и иммуногистохимической оценки ксенографтов опухоли человека (рака поджелудочной железы человека) и внутренних органов иммунодефицитных мышей после введения суспензии NK-клеток человека. Материал и методы. Предварительно на 4 мышах линии NBSGW были смоделированы ксенографты путем подкожного введения клеток опухолевой линии ASPC-1 (рак поджелудочной железы человека). На 24-е сутки исследования животным вводили суспензию NK-клеток мышам №2 и №4 внутривенно в количестве 8,8 млн и 9,2 млн, и подкожно – мышам №1 и №3 в количестве 10 млн и 14 млн NK-клеток, соответственно. На 28-е сутки исследований проводили эвтаназию животных и патоморфологическое исследование. Проводили рутинную гистологическую оценку внутренних органов мышей, иммуногистохимию образцов ксенографтов на наличие опухолевых клеток с антителами Cytokeratin 7 и Pan-Cytokeratin, а также ксенографтов и внутренних органов мышей на наличие CD56+ клеток. Результаты. Гистоархитектоника органов и тканей у животных была сохранена, в легких были обнаружены метастазы, инфильтрации СD56+ клеток в этой зоне в ткани легкого отмечено не было. В ксенографтах наблюдались единичные слабопозитивные СD56+ клетки, окрашивание мембраны которых было на грани видимости. В селезенке СD56+ клетки были единичные, также ярко окрашивалась часть сосудов ксенографта и селезенки (периферические нервные волокна, перициты). В образцах ксенографтов визуализировалась мелкокапельная дистрофия онкоцитов, воспалительная инфильтрация и индекс клеточного обновления был меньше или равен 1,0, что в комплексе свидетельствовало о слабо выраженных изменениях структуры опухоли. Заключение. Терапевтическое воздействие суспензии NK-клеток повышает опухолевый патоморфоз и ведет к увеличению области некрозов, в то время как индекс коэффициента клеточного обновления снижается. Необходимы дальнейшие исследования с увеличением дозы или кратности введения.</p></abstract><trans-abstract xml:lang="en"><p>Immuno-oncology is an actively developing area of applied research that has revolutionized cancer treatment. In particular, NK cells are classified as cytotoxic lymphocytes that play a crucial role in recognizing and eliminating malignant or infected cells. The aim of the study was to perform a histological and immunohistochemical  evaluation  of  human  tumor  xenografts  (human  pancreatic cancer) and internal organs of immunodeficient mice following the administration of a human NK cell suspension. Material and methods. Previously, xenografts were modeled on 4 NBSGW mice by subcutaneous administration of ASPC-1 tumor cells (human pancreatic cancer). On day 24 of the study, the animals were injected with NK cell suspension intravenously in the amount of 8.8 million and 9.2 million to mice №2 and №4, and subcutaneously in the amount of 10 million and 14 million NK cells to mice №1 and №3, respectively. On day 28 of the study, the animals were euthanized and pathomorphologically examined. Routine histological assessment of the internal organs of the mice, immunohistochemistry of xenograft samples for the presence of tumor cells with Cytokeratin 7 and Pan-Cytokeratin antibodies, as well as xenografts and internal organs of mice for the presence of CD56+ cells were performed. Results. The histoarchitecture of organs and tissues in animals was preserved, metastases were found in the lungs, no infiltration of CD56+ cells in this area of the lung tissue was noted. Single weakly positive CD56+ cells were observed in the xenografts, the membrane staining of which was barely visible. In the spleen, CD56+ cells were single, and part of the xenograft and spleen vessels (peripheral nerve fibers, pericytes) were also brightly stained. In the xenograft samples, small-droplet dystrophy of oncocytes, inflammatory infiltration and the cell renewal index were visualized less than or equal to 1.0, which together indicates mild changes in the tumor structure. Conclusion. The therapeutic effect of the NK cell suspension increases tumor pathomorphism, the areas of necrosis increase, while the cell renewal coefficient index decreases, but further studies are needed with an increase in the dose or frequency of administration.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>иммуногистохимия</kwd><kwd>гистология</kwd><kwd>NK-клетки</kwd><kwd>ксенографт опухоли</kwd><kwd>иммунодефицитные мыши</kwd></kwd-group><kwd-group xml:lang="en"><kwd>immunohistochemistry</kwd><kwd>histology</kwd><kwd>NK cells</kwd><kwd>tumor xenograft</kwd><kwd>immunodeficient mice</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Абакушина Е.В., Кузьмина Е.Г., Коваленко Е.И. Основные свойства и функции NK-клеток человека. Иммунология. 2012;33 (4):220–224.</mixed-citation><mixed-citation xml:lang="en">Abakushina EV, Kuz'mina EG, Kovalenko EI. Osnovnye svoistva i funktsii NK-kletok cheloveka. Immunologiya. 2012;33 (4):220–224. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Артемьева А.С., Мурашкина А.А., Рогачев М.В. Иммуногистохимия: основы, методические подходы, группы маркеров: Учебное пособие. СПб.: 2020. 76.</mixed-citation><mixed-citation xml:lang="en">Artem'eva AS, Murashkina AA, Rogachev MV. Immunogistokhimiya: osnovy, metodicheskie podkhody, gruppy markerov: Uchebnoe posobie. SPb.: 2020. 76. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Алдушкина Ю.В., Анисимова Н.Ю., Грицай А.Н., Новрузов К.М., Должикова Ю.И., Одарюк О.А. и др. Клиническая значимость обнаружения микрометастазов в лимфатических узлах при раке яичников. Российский биотерапевтический журнал. 2023;22(2):20–26. doi: 10.17650/1726-9784-2023-22-2-20-26.</mixed-citation><mixed-citation xml:lang="en">Aldushkina YuV, Anisimova NYu, Gritsai AN, Novruzov KM, Dolzhikova YuI, Odaryuk OA, et. al. Klinicheskaya znachimost' obnaruzheniya mikrometastazov v limfaticheskikh uzlakh pri rake yaichnikov. Rossiiskii bioterapevticheskii zhurnal. 2023;22(2):20–26. (In Russ.). doi: 10.17650/1726-9784-2023-22-2-20-26.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Болдышевская М.А., Таширева Л.А., Андрюхова Е.С., Дронова Т.А., Вторушин С.В., Перельмутер В.М. Неструктурная роль цитокератинов при злокачественных новообразованиях. Успехи молекулярной онкологии. 2023;10:76–84. doi: 10.17650/2313-805X-2023-10-4-76-85.</mixed-citation><mixed-citation xml:lang="en">Boldyshevskaya MA, Tashireva LA, Andryukhova ES, Dronova TA, Vtorushin SV, Perel'muter VM. Nestrukturnaya rol' tsitokeratinov pri zlokachestvennykh novoobrazovaniyakh. Uspekhi molekulyarnoi onkologii. 2023;10:76–84. (In Russ.). doi: 10.17650/2313-805X-2023-10-4-76-85.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Боробова Е.А., Жеравин А.А. Натуральные киллеры в иммунотерапии онкологических заболеваний. Сибирский онкологический журнал. 2018;17(6):97–104. doi: 10.21294/1814-4861-2018-17-6-97-104.</mixed-citation><mixed-citation xml:lang="en">Borobova EA, Zheravin AA. Natural'nye killery v immunoterapii onkologicheskikh zabolevanii. Sibirskii onkologicheskii zhurnal. 2018;17(6):97-104. (In Russ.). doi: 10.21294/1814-4861-2018-17-6-97-104.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Гуревич Л.Е., Казанцева И.А., Корсакова Н.А., Бобров М.А. Значение иммуногистохимии для таргетной терапии и прогнозирования в онкологии. Альманах клинической медицины. 2012;27:27–34.</mixed-citation><mixed-citation xml:lang="en">Gurevich LE, Kazantseva IA, Korsakova NA, Bobrov MA. Znachenie immunogistokhimii dlya targetnoi terapii i prognozirovaniya v onkologii. Al'manakh klinicheskoi meditsiny. 2012;27:27–34. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Гуревич Л.Е., Корсакова Н.А., Воронкова И.А., Казанцева И.А., Ашевская В.Е., Титов А.Г., и др. Прогностическое и дифференциально-диагностическое значение экспрессии цитокератинов 7 и 19 и тиреоидного фактора транскрипции-1 в нейроэндокринных опухолях легких разной степени злокачественности. Альманах клинической медицины. 2016;44(5):613–23.</mixed-citation><mixed-citation xml:lang="en">Gurevich LE, Korsakova NA, Voronkova IA, Kazantseva IA, Ashevskaya VE, Titov AG, et. al. Prognosticheskoe i differentsial'no- diagnosticheskoe znachenie ekspressii tsitokeratinov 7 i 19 i tireoidnogo faktora transkriptsii-1 v neiroendokrinnykh opukholyakh legkikh raznoi stepeni zlokachestvennosti. Al'manakh klinicheskoi meditsiny. 2016;44(5):613– 23. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, et. al. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate. 2011 Jun 1;71(8):846-56. doi: 10.1002/pros.21301.</mixed-citation><mixed-citation xml:lang="en">Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, et. al. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate. 2011 Jun 1;71(8):846-56. doi: 10.1002/pros.21301.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bayrak R, Haltas H, Yenidunya S. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody. Diagn Pathol. 2012 Jan 23;7:9. doi: 10.1186/1746-1596-7-9.</mixed-citation><mixed-citation xml:lang="en">Bayrak R, Haltas H, Yenidunya S. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody. Diagn Pathol. 2012 Jan 23;7:9. doi: 10.1186/1746-1596-7-9.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Biassoni R. Human natural killer receptors, co-receptors, and their ligands. Curr Protoc Immunol. 2009; Chapter 14: 14.10.1-14.10.40. doi: 10.1002/cpim.47.</mixed-citation><mixed-citation xml:lang="en">Biassoni R. Human natural killer receptors, co-receptors, and their ligands. Curr Protoc Immunol. 2009; Chapter 14: 14.10.1-14.10.40. doi: 10.1002/cpim.47.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013 Jul 25;39(1):1-10. doi: 10.1016/j.immuni.2013.07.012.</mixed-citation><mixed-citation xml:lang="en">Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013 Jul 25;39(1):1-10. doi: 10.1016/j.immuni.2013.07.012.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018 Nov;18(11):671-688. doi: 10.1038/s41577-018-0061-z. Erratum in: Nat Rev Immunol. 2018 Nov;18(11):726. doi: 10.1038/s41577-018-0077-4.</mixed-citation><mixed-citation xml:lang="en">Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018 Nov;18(11):671-688. doi: 10.1038/s41577-018-0061-z. Erratum in: Nat Rev Immunol. 2018 Nov;18(11):726. doi: 10.1038/s41577-018-0077-4.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">DeLellis RA, Shin SJ, Treaba OD. Chapter 10: Immunohistology of endocrine tumors. In: Dabbs D. J., editor. Diagnostic immunohistochemistry: theranostic and genomic applications. 3rd ed. Philadelphia: Saunders Elsevier; 2010;291–329. doi: 10.1016/B978-1-4160-5766-6.00014-5.</mixed-citation><mixed-citation xml:lang="en">DeLellis RA, Shin SJ, Treaba OD. Chapter 10: Immunohistology of endocrine tumors. In: Dabbs D. J., editor. Diagnostic immunohistochemistry: theranostic and genomic applications. 3rd ed. Philadelphia: Saunders Elsevier; 2010;291–329. doi: 10.1016/B978-1-4160-5766-6.00014-5.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Dobiasch S, Kampfer S, Steiger K, Schilling D, Fischer JC, Schmid TE, et. al. Histopathological Tumor and Normal Tissue Responses after 3D-Planned Arc Radiotherapy in an Orthotopic Xenograft Mouse Model of Human Pancreatic Cancer. Cancers (Basel). 2021 Nov 12;13(22):5656. doi: 10.3390/cancers13225656.</mixed-citation><mixed-citation xml:lang="en">Dobiasch S, Kampfer S, Steiger K, Schilling D, Fischer JC, Schmid TE, et. al. Histopathological Tumor and Normal Tissue Responses after 3D-Planned Arc Radiotherapy in an Orthotopic Xenograft Mouse Model of Human Pancreatic Cancer. Cancers (Basel). 2021 Nov 12;13(22):5656. doi: 10.3390/cancers13225656.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Dum D, Menz A, Völkel C, De Wispelaere N, Hinsch A, Gorbokon N, et. al. Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers. Exp Mol Pathol. 2022 Jun;126:104762. doi: 10.1016/j.yexmp.2022.104762.</mixed-citation><mixed-citation xml:lang="en">Dum D, Menz A, Völkel C, De Wispelaere N, Hinsch A, Gorbokon N, et. al. Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers. Exp Mol Pathol. 2022 Jun;126:104762. doi: 10.1016/j.yexmp.2022.104762.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Galli F, Rapisarda AS, Stabile H, Malviya G, Manni I, Bonanno E, et. al. In Vivo Imaging of Natural Killer Cell Trafficking in Tumors. J Nucl Med. 2015 Oct;56(10):1575-80. doi: 10.2967/jnumed.114.152918.</mixed-citation><mixed-citation xml:lang="en">Galli F, Rapisarda AS, Stabile H, Malviya G, Manni I, Bonanno E, et. al. In Vivo Imaging of Natural Killer Cell Trafficking in Tumors. J Nucl Med. 2015 Oct;56(10):1575-80. doi: 10.2967/jnumed.114.152918.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711.</mixed-citation><mixed-citation xml:lang="en">June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SW, Roh J, Park CS. Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips. J Pathol Transl Med. 2016 Nov;50(6):411-418. doi: 10.4132/jptm.2016.08.08.</mixed-citation><mixed-citation xml:lang="en">Kim SW, Roh J, Park CS. Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips. J Pathol Transl Med. 2016 Nov;50(6):411-418. doi: 10.4132/jptm.2016.08.08.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Maskalenko NA, Zhigarev D, Campbell KS. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat Rev Drug Discov. 2022 Aug;21(8):559-577. doi: 10.1038/s41573-022-00413-7.</mixed-citation><mixed-citation xml:lang="en">Maskalenko NA, Zhigarev D, Campbell KS. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat Rev Drug Discov. 2022 Aug;21(8):559-577. doi: 10.1038/s41573-022-00413-7.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Parodi M, Astigiano S, Carrega P, Pietra G, Vitale C, Damele L, et. al. Murine models to study human NK cells in human solid tumors. Front Immunol. 2023 Jun 14;14:1209237. doi: 10.3389/fimmu.2023.1209237.</mixed-citation><mixed-citation xml:lang="en">Parodi M, Astigiano S, Carrega P, Pietra G, Vitale C, Damele L, et. al. Murine models to study human NK cells in human solid tumors. Front Immunol. 2023 Jun 14;14:1209237. doi: 10.3389/fimmu.2023.1209237.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Pergolini I, Morales-Oyarvide V, Mino-Kenudson M, Honselmann KC, Rosenbaum MW, Nahar S, et. al. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. PLoS One. 2017 Aug 30;12(8):e0182855. doi: 10.1371/journal.pone.0182855.</mixed-citation><mixed-citation xml:lang="en">Pergolini I, Morales-Oyarvide V, Mino-Kenudson M, Honselmann KC, Rosenbaum MW, Nahar S, et. al. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. PLoS One. 2017 Aug 30;12(8):e0182855. doi: 10.1371/journal.pone.0182855.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Shin E, Bak SH, Park T, Kim JW, Yoon SR, Jung H, et. al. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond. Front Immunol. 2023 Jul 18;14:1192907. doi: 10.3389/fimmu.2023.1192907.</mixed-citation><mixed-citation xml:lang="en">Shin E, Bak SH, Park T, Kim JW, Yoon SR, Jung H, et. al. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond. Front Immunol. 2023 Jul 18;14:1192907. doi: 10.3389/fimmu.2023.1192907.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007 May;117(5):1137-46. doi: 10.1172/JCI31405.</mixed-citation><mixed-citation xml:lang="en">Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007 May;117(5):1137-46. doi: 10.1172/JCI31405.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Tarazona R., Lopez-Sejas N., Guerrero B., Hassouneh F., Valhondo I., Pera A., et. al. Current progress in NK cell biology and NK cell-based cancer immunotherapy. Cancer Immunol Immunother. 2020;69(5):879-899. doi: 10.1007/s00262-020-02532-9.</mixed-citation><mixed-citation xml:lang="en">Tarazona R., Lopez-Sejas N., Guerrero B., Hassouneh F., Valhondo I., Pera A., et. al. Current progress in NK cell biology and NK cell-based cancer immunotherapy. Cancer Immunol Immunother. 2020;69(5):879-899. doi: 10.1007/s00262-020-02532-9.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Tseng WW, Winer D, Kenkel JA, Choi O, Shain AH, Pollack JR, French R, Lowy AM, Engleman EG. Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host. Clin Cancer Res. 2010 Jul 15;16(14):3684-95. doi: 10.1158/1078-0432.CCR-09-2384.</mixed-citation><mixed-citation xml:lang="en">Tseng WW, Winer D, Kenkel JA, Choi O, Shain AH, Pollack JR, French R, Lowy AM, Engleman EG. Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host. Clin Cancer Res. 2010 Jul 15;16(14):3684-95. doi: 10.1158/1078-0432.CCR-09-2384.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023;2:90-105. doi: 10.1038/s41577-022-00732-1</mixed-citation><mixed-citation xml:lang="en">Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023;2:90-105. doi: 10.1038/s41577-022-00732-1</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
